Dr. Robert M. Jacobson , MD
Colon & Rectal Surgery • Dallas, TX
3409 Worth St, Suite 500
Dallas, TX 752462029
This profile restates public CMS/NPPES data; T-MedInfo gives no medical advice — consult a licensed professional, and call 911 for emergencies.
-
Dr. Robert Jacobson is listed in NPPES under Colon & Rectal Surgery.
-
NPI assigned on November 2, 2006; this date does not establish years in practice.
-
Published CMS data list 418 Original Medicare Part B services in 2021.
Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2021. Published rows only; this is not a quality measure.
-
Published Part B service records, 2021:
- 99213 — Established patient outpatient office visit: 210 service units.
- 45300 — Diagnostic exam of rectum and lower large bowel using an endoscope: 40 service units.
- G0105 — Colorectal cancer screening; colonoscopy on individual at high risk: 36 service units.
Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2021. Units differ by code; these are not visits or a measure of quality.
CPT® only copyright 2020 American Medical Association. All rights reserved. Service names are shortened from CPT Consumer Friendly Descriptors (CMS data, 2021). CPT notice
See all 8 records in the table · Guide: How to read Medicare Part B data
-
Published CMS data list 460 Medicare Part D prescriptions, including refills, in 2021.
Source: CMS, Medicare Part D Prescribers – by Provider and Drug, 2021. Published rows only; this is not a quality measure.
-
Published Part D records, 2021:
- Suprep (Sodium, Potassium,mag Sulfates) — 48 prescription fills, including refills.
- Diphenoxylate-Atropine (Diphenoxylate Hcl/Atropine) — 47 prescription fills, including refills.
- Acetaminophen-Codeine (Acetaminophen With Codeine) — 27 prescription fills, including refills.
Source: CMS, Medicare Part D Prescribers – by Provider and Drug, 2021. Drug names come from pharmacy claims. Listing a drug here is not an endorsement or a recommendation.
See all 20 records in the table · Guide: How to read Medicare Part D prescriber data
-
Medicare Part B services went from 1,839 in 2017 to 418 in 2021.
Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2017–2021.
Practice Location & Contact Primary Location
3409 Worth St
Suite 500
Dallas, TX 752462029
Matched by practice address or phone in NPPES. A shared address or phone does not confirm that this clinician works there.
What Public CMS Data Show
Colon & Rectal Surgery: NPPES taxonomy is a reported classification, not proof of board certification.
Medicare-allowed amount
About $54,562 in 2021
The total amount Medicare approved for these services in 2021. It includes what Medicare paid and what patients or their other insurance owed, such as the deductible and coinsurance.
It shows the total cost of this clinician's Original Medicare services under Medicare's fee rules.
What this does not show: Medicare-allowed amount
This is not the clinician's income. Part of it can go to a clinic or group practice, staff, equipment or drugs. It is not the price you will pay.
Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2021.
Paid by Medicare
About $40,454 in 2021
The part of the Medicare-allowed amount that Medicare itself paid in 2021, after patients' deductibles and coinsurance.
The gap between the allowed amount and this number is roughly what patients and their other insurance paid.
What this does not show: Paid by Medicare
This is not the clinician's income and not a measure of quality.
Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2021.
30-day fills
561 standardized 30-day fills in 2021
CMS converts prescriptions to 30-day supplies so they can be compared. A 90-day prescription counts as about three 30-day fills.
What this does not show: 30-day fills
It is not a count of patients and not a measure of quality.
Part D drug cost
$1,208,564 in 2021
The total cost of these prescriptions in 2021, paid by Medicare drug plans, patients and other payers together.
It shows the total spending on drugs this clinician prescribed, not what any one patient paid.
What this does not show: Part D drug cost
A higher cost often reflects the type of medicines a specialty uses. It is not your out-of-pocket cost and not a measure of quality.
Source: CMS, Medicare Part D Prescribers – by Provider and Drug, 2021.
Open Payments general payments, program year 2025
All general payments: $24,042.13 across 19 records.
By nature of payment (3 largest of 4)
- Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program: $16,249.50 across 3 records.
- Consulting Fee: $5,416.50 across 1 record.
- Travel and Lodging: $1,967.02 across 8 records.
Reporting-company totals
- Takeda Pharmaceuticals U.S.A., Inc.: $24,042.13 across 19 records.
A reported payment does not necessarily mean the financial relationship is improper and is not a measure of care quality. Clinicians can review and dispute these records.
Source: Calculated by T-MedInfo from CMS Open Payments general-payment records for program year 2025 (published June 30, 2026).
NPI first issued
2006
The year this clinician's National Provider Identifier (NPI) was issued. An NPI is a unique 10-digit ID that US health care providers use for billing.
What this does not show: NPI first issued
NPIs have been issued only since 2005, so this year is not necessarily when the clinician started practicing.
Source: CMS NPPES NPI Registry.
Medicare assignment not listed
CMS data do not show whether this clinician accepts Medicare assignment. This does not mean they do not accept Medicare. Ask the office.
Medicare assignment applies to Original Medicare. It does not tell you whether the clinician is in a Medicare Advantage plan's network, accepts other insurance, or is taking new patients.
Source: CMS Doctors and Clinicians; Medicare.gov, “Does your provider accept Medicare as full payment?”
No telehealth indicator
CMS shows this indicator only when recent Medicare claims include telehealth services. The clinician may still offer telehealth; ask the office.
Source: CMS, Telehealth Indicator on Medicare Care Compare (fact sheet, January 2023); CMS Doctors and Clinicians.
Enrolled in Medicare (PECOS)
Dr. Jacobson has a Medicare enrollment record in PECOS, the CMS system clinicians use to enroll so they can bill Medicare or order services for people with Medicare.
It does not show whether the clinician accepts assignment, is in your plan's network, or is taking new patients.
Source: CMS Medicare Fee-For-Service Public Provider Enrollment (PECOS); CMS Order and Referring file.
Can order Medicare-covered services
CMS lists Dr. Jacobson as eligible to order or refer Medicare Part B clinical laboratory and imaging services, durable medical equipment (DME) and home health services for people with Medicare.
Medicare pays for these items and services only when they are ordered by an eligible clinician.
What this does not show: Can order Medicare-covered services
It does not mean the clinician offers these services directly.
Source: CMS Medicare Fee-For-Service Public Provider Enrollment (PECOS); CMS Order and Referring file.
Compared with the same specialty in Dallas and Texas
Billing and prescribing volume is not a quality rating.
Medicare Part B
Comparisons use 2024 data. The latest CMS data for Dr. Jacobson are from 2021.
Medicare Part D
Comparisons use 2024 data. The latest CMS data for Dr. Jacobson are from 2021.
32 active clinicians are listed under Colon & Rectal Surgery with a practice address in Dallas, TX (209 in Texas).
Addresses are self-reported to NPPES and may be out of date.
Telehealth indicator in Dallas
43.8% of these 32 clinicians have the CMS telehealth indicator.
75% of these 32 clinicians are listed by CMS as accepting Medicare assignment.
CMS data by year
Changes may reflect reporting, coverage or privacy limits, not changes in care quality.
-
Medicare Part B services
Medicare Part B services decreased 77% from 1,839 in 2017 to 418 in 2021.
- 2017: 1,839
- 2018: 1,621
- 2019: 1,543
- 2020: 1,100
- 2021: 418
-
Medicare-allowed amount
Medicare-allowed amount decreased 70% from $183,050 in 2017 to $54,562 in 2021.
- 2017: $183,050
- 2018: $185,354
- 2019: $169,461
- 2020: $120,732
- 2021: $54,562
-
Paid by Medicare
Paid by Medicare decreased 72% from $144,565 in 2017 to $40,454 in 2021.
- 2017: $144,565
- 2018: $146,650
- 2019: $131,569
- 2020: $94,541
- 2021: $40,454
-
Medicare Part D prescriptions
Medicare Part D prescriptions decreased 72% from 1,616 in 2017 to 460 in 2021.
- 2017: 1,616
- 2018: 1,444
- 2019: 1,294
- 2020: 1,092
- 2021: 460
-
30-day fills
30-day fills decreased 69% from 1,797 in 2017 to 561 in 2021.
- 2017: 1,797
- 2018: 1,602
- 2019: 1,438
- 2020: 1,270
- 2021: 561
-
Part D drug cost
Part D drug cost increased 67% from $722,916 in 2017 to $1,208,564 in 2021.
- 2017: $722,916
- 2018: $1,308,330
- 2019: $2,178,258
- 2020: $1,916,032
- 2021: $1,208,564
-
Industry payments (Open Payments)
Industry payments (Open Payments) increased 176% from $8,715.81 in 2021 to $24,042.13 in 2025.
- 2021: $8,715.81
- 2022: $24,389.21
- 2023: $54,038.12
- 2024: $6,512.79
- 2025: $24,042.13
Sources: CMS Medicare Physician & Other Practitioners (2021), CMS Medicare Part D Prescribers (2021), CMS Open Payments (2025), CMS Doctors and Clinicians, CMS NPPES NPI Registry. Specialty names follow the NUCC Health Care Provider Taxonomy.
Text: T-MedInfo · Report an error.
Pharma & Medical Device Financial Disclosures
Payments and other transfers of value that drug and medical device companies reported to CMS Open Payments
Program year 2025 (payments made January 1 – December 31, 2025): 19 records totaling $24,042.13.
| Manufacturer | Payment Nature | Product | Type | Amount ($) |
|---|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. |
Consulting Fee
Cash or cash equivalent
|
GATTEX | General | $5,416.50 |
| Takeda Pharmaceuticals U.S.A., Inc. |
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
Cash or cash equivalent
|
GATTEX | General | $5,416.50 |
| Takeda Pharmaceuticals U.S.A., Inc. |
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
Cash or cash equivalent
|
GATTEX | General | $5,416.50 |
| Takeda Pharmaceuticals U.S.A., Inc. |
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
Cash or cash equivalent
|
GATTEX | General | $5,416.50 |
| Takeda Pharmaceuticals U.S.A., Inc. |
Travel and Lodging
In-kind items and services
|
GATTEX | General | $511.91 |
| Takeda Pharmaceuticals U.S.A., Inc. |
Travel and Lodging
In-kind items and services
|
GATTEX | General | $392.60 |
| Takeda Pharmaceuticals U.S.A., Inc. |
Travel and Lodging
In-kind items and services
|
GATTEX | General | $322.05 |
| Takeda Pharmaceuticals U.S.A., Inc. |
Travel and Lodging
In-kind items and services
|
GATTEX | General | $223.10 |
| Takeda Pharmaceuticals U.S.A., Inc. |
Travel and Lodging
In-kind items and services
|
GATTEX | General | $182.62 |
| Takeda Pharmaceuticals U.S.A., Inc. |
Travel and Lodging
In-kind items and services
|
GATTEX | General | $147.37 |
| Takeda Pharmaceuticals U.S.A., Inc. |
Travel and Lodging
In-kind items and services
|
GATTEX | General | $147.37 |
| Takeda Pharmaceuticals U.S.A., Inc. |
Food and Beverage
In-kind items and services
|
GATTEX | General | $118.70 |
| Takeda Pharmaceuticals U.S.A., Inc. |
Food and Beverage
In-kind items and services
|
GATTEX | General | $102.18 |
| Takeda Pharmaceuticals U.S.A., Inc. |
Food and Beverage
In-kind items and services
|
GATTEX | General | $61.37 |
| Takeda Pharmaceuticals U.S.A., Inc. |
Food and Beverage
In-kind items and services
|
GATTEX | General | $47.41 |
| Takeda Pharmaceuticals U.S.A., Inc. |
Travel and Lodging
In-kind items and services
|
GATTEX | General | $40.00 |
| Takeda Pharmaceuticals U.S.A., Inc. |
Food and Beverage
In-kind items and services
|
GATTEX | General | $31.97 |
| Takeda Pharmaceuticals U.S.A., Inc. |
Food and Beverage
In-kind items and services
|
GATTEX | General | $25.09 |
| Takeda Pharmaceuticals U.S.A., Inc. |
Food and Beverage
In-kind items and services
|
GATTEX | General | $22.39 |
Source: CMS Open Payments, program year 2025, released June 30, 2026.
Performed Procedures & Service Volume
CPT® is a registered trademark of the American Medical Association. CPT codes, descriptions and other data only are copyright 2016–2020 American Medical Association. All rights reserved. Applicable FARS/HHSARS apply. Descriptions of CPT codes are the AMA's CPT Consumer Friendly Descriptors as published by CMS in the Medicare Physician & Other Practitioners – by Provider and Service data, 2017–2021; they are plain-language summaries, not for clinical coding or documentation. HCPCS Level II codes and descriptions are from CMS. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.
| HCPCS Code | Services | Patients | Submitted Charge | Medicare Allowed |
|---|---|---|---|---|
|
99213
Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
|
210 | 135 | $105.00 | $92.81 |
|
45300
Diagnostic exam of rectum and lower large bowel using an endoscope
|
40 | 37 | $190.00 | $138.08 |
|
G0105
Colorectal cancer screening; colonoscopy on individual at high risk
|
36 | 36 | $527.72 | $186.11 |
|
99204
New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
|
34 | 34 | $280.00 | $170.22 |
|
45380
Biopsy of large bowel using a flexible endoscope
|
33 | 33 | $1195.00 | $196.38 |
|
45385
Removal of polyps or growths of large bowel using an endoscope with mechanical snare
|
23 | 23 | $855.00 | $255.54 |
|
99441
Telephone medical discussion with physician, 5-10 minutes
|
21 | 15 | $78.00 | $55.43 |
|
G0121
Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk
|
21 | 21 | $563.24 | $168.56 |
Source: CMS Part B by Provider and Service, 2021; services under 11 beneficiaries omitted by CMS. Privacy limits
Submitted charges are billed amounts, not a price quote for your visit.
Medicare Part D Prescribing Profile & Medications
Medicare Part D prescriptions filled, including refills, in 2021.
| Brand Name | Generic Name | Prescriptions | Day Supply | Total Cost | Patients |
|---|---|---|---|---|---|
| Suprep | Sodium, Potassium,mag Sulfates | 48 | 114 | $5,305.11 | 47 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 47 | 1,133 | $5,098.30 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 27 | 260 | $409.98 | — |
| Tramadol Hcl | Tramadol Hcl | 27 | 297 | $83.99 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 586 | $427.70 | 13 |
| Trulance | Plecanatide | 25 | 1,155 | $18,053.32 | — |
| Clenpiq | Sod Picosulf/Mag Ox/Citric Ac | 25 | 89 | $3,947.17 | 25 |
| Dexilant | Dexlansoprazole | 23 | 1,170 | $12,918.02 | — |
| Mesalamine | Mesalamine | 23 | 1,500 | $24,128.66 | — |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 21 | 329 | $593.87 | — |
| Diazepam | Diazepam | 21 | 374 | $115.63 | — |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | 726 | $298.20 | — |
| Ondansetron Odt | Ondansetron | 18 | 250 | $361.94 | 11 |
| Linzess | Linaclotide | 18 | 715 | $11,791.95 | — |
| Gattex | Teduglutide | 18 | 540 | $1,048,463.06 | — |
| Opium Tincture | Opium Tincture | 17 | 424 | $26,680.47 | — |
| Xifaxan | Rifaximin | 16 | 507 | $47,977.36 | — |
| Pantoprazole Sodium | Pantoprazole Sodium | 15 | 990 | $224.69 | — |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | 348 | $1,290.58 | — |
| Procto-Med Hc | Hydrocortisone | 12 | 241 | $393.70 | — |
Source: CMS Part D by Provider and Drug, 2021; rows below 11 claims omitted by CMS; volume isn’t quality. Privacy limits
Specialties & License Numbers Reported to NPPES
NUCC Taxonomy Code: 208C00000X
A colon and rectal surgeon is trained to diagnose and treat various diseases of the intestinal tract, colon, rectum, anal canal and perianal area by medical and surgical means. This specialist also deals with other organs and tissues (such as the liver, urinary and female reproductive system) involved with primary intestinal disease.
NUCC Taxonomy Code: 174400000X
An individual educated and trained in an applied knowledge discipline used in the performance of work at a level requiring knowledge and skills beyond or apart from that provided by a general education or liberal arts degree.
Additional State Medicaid & Healthcare Payer Identifiers
Medicare (PECOS) Enrollment & Ordering Eligibility
Source: CMS PECOSPRACTITIONER - COLORECTAL SURGERY (PROCTOLOGY)
I20110106000957
TX
6901821040
Sources: CMS Provider Enrollment and Order and Referring. Medicare enrollment is a billing status, not an accreditation or quality rating.
Clinicians Sharing This Practice Address or Phone
Clinicians sharing this NPPES address, phone or fax; a shared contact does not mean they work together.
Colon & Rectal Surgery
Doctor of Medicine (M.D.)
Colon & Rectal Surgery
Doctor of Medicine (M.D.)
Colon & Rectal Surgery
Doctor of Medicine (M.D.)
Colon & Rectal Surgery
Doctor of Medicine (M.D.), Master of Public Health
Career & Practice History
NPI enumerated November 02, 2006.
No changes to the name, practice address, taxonomy or NPI status in this record have been observed in the monthly NPPES data files from January 2017 to August 2026.
NPI Administrative Meta
Other Colon & Rectal Surgery Specialists in Dallas
- Dr. Warren Lichliter, MD
- Dr. Edward Franko, MD
- Dr. Fadwa Ali, MD
- Dr. Clifford Simmang, MD
- Dr. Abier Abdelnaby, MD
- Dr. J. Marcus Downs, MD
Mailing Address
3409 Worth St, Suite 500
Dallas, TX 752462029
Phone: 2148241730